Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | 0.00% | +6.45% | +133.63% |
Sales 2024 * | 72.54M 5.81B | Sales 2025 * | 68.35M 5.47B | Capitalization | 242M 19.4B |
---|---|---|---|---|---|
Net income 2024 * | -168M -13.45B | Net income 2025 * | -167M -13.37B | EV / Sales 2024 * | 1.76 x |
Net cash position 2024 * | 115M 9.19B | Net cash position 2025 * | 281M 22.53B | EV / Sales 2025 * | -0.57 x |
P/E ratio 2024 * |
-1.56
x | P/E ratio 2025 * |
-1.97
x | Employees | 137 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.18% |
Latest transcript on Nektar Therapeutics
1 week | +6.45% | ||
Current month | +41.30% | ||
1 month | +49.14% | ||
3 months | +159.33% | ||
6 months | +178.60% | ||
Current year | +133.63% |
Managers | Title | Age | Since |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 31/12/06 |
Robert Chess
CHM | Chairman | 66 | 30/11/91 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 16/04/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 31/12/09 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 31/07/00 |
Robert Chess
CHM | Chairman | 66 | 30/11/91 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.32% | 16 M€ | -8.49% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.32 | 0.00% | 559,095 |
25/04/24 | 1.32 | -4.35% | 1,054,027 |
24/04/24 | 1.38 | -2.82% | 958,333 |
23/04/24 | 1.42 | +4.41% | 1,101,026 |
22/04/24 | 1.36 | +9.68% | 1,970,248 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+133.63% | 242M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- NKTR Stock